Ø GSDP Framework to Enhance Regulatory
Oversight and Accountability in Pharmaceutical Supply Chain
Ø Proposed Measures to Ensure Quality,
Safety and Integrity of Pharmaceutical Products from Manufacturer to Patient
The
Union Ministry of Health and Family Welfare has proposed incorporating Good Storage and Distribution Practices
(GSDP) guidelines for pharmaceutical products into the Drugs
Rules, 1945, to ensure quality and safety throughout the pharmaceutical supply
chain.
1. Objective: To maintain the quality, safety, efficacy
and integrity of pharmaceutical products from the manufacturer or importer up
to their supply to the patient.
2. Regulatory Framework: The proposal builds upon GSDP guidelines
developed by the Central Drugs Standard Control Organisation (CDSCO).
3. Coverage: GSDP requirements will cover all major
stages of pharmaceutical distribution, including:
o Procurement
and purchasing.
o Storage
and warehousing.
o Distribution
and transportation.
o Documentation
and record-keeping.
4. Supply Chain Risks: The guidelines aim to prevent:
o Deterioration
of pharmaceutical products.
o Contamination
and product mix-ups.
o Falsification
of medicines.
o Diversion
and unauthorised distribution.
5. Stakeholders Covered: The framework will enhance accountability
among:
o Manufacturers
and importers.
o Wholesalers
and distributors.
o Stockists
and other entities involved in pharmaceutical distribution.
6. Storage and Transportation: Pharmaceutical products must be
maintained under specified quality and environmental conditions throughout
storage and transportation.
7. Regulatory Oversight: Incorporation into the Drugs Rules, 1945,
will strengthen inspection, monitoring and enforcement by Central and State
drug-control authorities.
8. Traceability and Accountability: Improved documentation, record-keeping
and traceability will facilitate regulatory supervision and accountability
across the distribution chain.
·
Strengthen India's pharmaceutical
quality-management system.
·
Minimise risks of deterioration,
contamination, falsification and diversion.
·
Ensure that product quality established
during manufacturing is maintained throughout storage and distribution.
·
Improve availability of medicines of
assured quality to patients and healthcare providers.
Effect of the Proposed Amendment: GSDP requirements will become part of the statutory regulatory framework under the Drugs Rules, 1945, strengthening quality control and accountability across the pharmaceutical supply chain, from manufacturing or importation to the final patient.
[ABS News Service/20.11.2026]
The Union Ministry of Health and
Family Welfare has proposed the incorporation of Good Storage and Distribution
Practices (GSDP) guidelines for pharmaceutical products into the Drugs Rules,
1945. The proposal aims to ensure that the quality, safety, efficacy and
integrity of pharmaceutical products are maintained throughout the distribution
chain, from the manufacturer or importer to the point of supply to the patient.
The proposed framework builds upon
the GSDP guidance developed by the Central Drugs Standard Control Organisation
(CDSCO). The guidelines seek to ensure the quality and identity of
pharmaceutical products at every stage of the distribution process, including
procurement, purchasing, storage, distribution, transportation, documentation
and record-keeping.
Maintaining appropriate storage and
distribution conditions is essential to preserving the quality and integrity of
pharmaceutical products beyond the manufacturing stage. The proposed GSDP
framework seeks to address potential risks associated with their handling and
movement across the supply chain, including deterioration, contamination,
mix-ups, falsification, diversion and unauthorised distribution.
The incorporation of GSDP
requirements into the Drugs Rules, 1945, is expected to strengthen the
regulatory framework governing pharmaceutical distribution and support
effective regulatory oversight, inspection and enforcement by the Central and
State drug-control authorities. It will also promote robust documentation,
record-keeping and traceability, while enhancing accountability among
manufacturers, importers, wholesalers, distributors, stockists and other
entities involved in the distribution process.
The proposed guidelines will further
strengthen assurance that pharmaceutical products remain within specified
quality and environmental conditions during storage and transportation, thereby
reducing the risk of deterioration, contamination, mix-ups, falsification,
diversion and unauthorised distribution. This will support the availability of
pharmaceutical products of assured quality to patients and healthcare
providers.
The proposed amendment represents an
important step towards strengthening India's pharmaceutical quality-management
system and ensuring that the quality established at the manufacturing stage is
maintained throughout the supply chain until the product reaches the patient.
Stakeholders and members of the public
are invited to submit their objections and suggestions, if any, to the Under
Secretary (Drugs Regulation), Ministry of Health and Family Welfare, Government
of India, U-6, Work Hall, C Wing, First Floor, Kartavya
Bhawan-1, New Delhi - 110001, or via email at drugsdiv-mohfw[at]gov[dot]in.